Medical Marijuana Inc (MJNA)

[Art Vandeley]

Going forward, the Company’s board of directors intends to broaden the current operations of the Company to include development of pharmaceutical and nutriceutical products, manufacturing facilities, genetically and nano-controlled botanical products, extraction and purification of biomaterials technologies. These activities are anticipated to include the following:

a)
Supporting a clinical trial at the VU University of Amsterdam, The Netherlands in collaboration with the University of Plymouth, GB for a novel (patent pending) delivery form of cannabinoids for treatment of pain and spasticity in patients with multiple sclerosis. The anticipated duration of the trials prior to FDA/ EMA registration is 24 months.
b)
Conducting research trials of a novel delivery mechanism (patent pending) for treatment of patients with ADHD.
c)
Contracting with Syncom BV, Gronigen, The Netherlands for provision of intellectual property for extraction and concentration of active pharmaceutical ingredients based on cannabinoids. The anticipated duration of the trials is 4 months.
d)
A land purchase in the city of Almere, in the province of Flevoland, The Netherlands for building of a state of the art FDA, EMA and GMP- compliant extraction facility as well as a factory for pharmaceutical and nutriceutical preparations.
e)
Negotiating with Italy, Spain and The Czech Republic for importation of pharmaceutical grade CBD-reach hemp oil to Europe and the USA.

http://www.sec.gov/Archives/edgar/data/1514946/000138730814000066/filename1.htm